Nektar Therapeutics (NKTR) Tops Q1 EPS by 97c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $66.84 --0%
Revenue Growth %: -11.4%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -11.4%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of $0.73, $0.97 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $20.11 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- FactSet acquires BCC Group to expand real-time market data platform
- CRH plc (CRH) PT Lowered to $135 at UBS, Buy Rating Maintained
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
